Pilocarpine Hydrochloride

Basic Information

Item Value
DrugBank ID DB01085
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 35

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 primary hereditary glaucoma KG + DL
2 oral candidiasis KG + DL
3 glaucoma 1, open angle KG + DL
4 open angle glaucoma KG + DL
5 osteoradionecrosis of the mandible KG + DL
6 commissural lip fistula KG + DL
7 burning mouth syndrome KG + DL
8 oral leukoedema KG + DL
9 chronic tic disorder KG + DL
10 extrapyramidal and movement disease KG + DL
11 benign shuddering attacks KG + DL
12 lingual-facial-buccal dyskinesia KG + DL
13 Axenfeld anomaly KG + DL
14 psychogenic movement disorders KG + DL
15 benign paroxysmal tonic upgaze of childhood with ataxia KG + DL
16 primary orthostatic tremor KG + DL
17 tremor-nystagmus-duodenal ulcer syndrome KG + DL
18 glaucoma KG + DL
19 fibroma of prostate KG + DL
20 benign reproductive system neoplasm KG + DL
21 benign prostate phyllodes tumor KG + DL
22 Brenner tumor KG + DL
23 male reproductive organ cancer KG + DL
24 androgen insensitivity syndrome KG + DL
25 early-onset familial noncirrhotic portal hypertension KG + DL
26 primitive portal vein thrombosis KG + DL
27 hepatoportal sclerosis KG + DL
28 idiopathic copper-associated cirrhosis KG + DL
29 hepatopulmonary syndrome KG + DL
30 salivary gland disease KG + DL
31 candidiasis KG + DL
32 acute pulmonary heart disease KG + DL
33 prostate leiomyoma KG + DL
34 hepatic porphyria KG + DL
35 prostate cancer/brain cancer susceptibility KG + DL

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search


Copyright © 2026 藥提醒科技有限公司 (yao.care). This report is for research purposes only and does not constitute medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.